MentionFox
Home › funding signals › Ochre Bio
Accelerator · announced

Ochre Bio (YC W20) — RNA medicines for liver diseases

Ochre Bio appears in Y Combinator's company directory in the Winter 2020 batch, listed 2020-03-12. RNA medicines for liver diseases.

Just raised? Share it.

Ochre Bio: Accepted into Y Combinator Winter 2020

What do you want to do with Ochre Bio?

Ochre Bio

New accelerator entry · 2020-03-12 · the record

Winter 2020
batch
50
people
Growth
stage
United Kingdom
region
Open the record →

In their words

Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.

What the record says

BatchWinter 2020
Announced2020-03-12
StageGrowth
StatusActive
Team size50
IndustryHealthcare
Sub-industryHealthcare -> Therapeutics
SectorsBiotech, Genomics
RegionsUnited Kingdom, Europe, Remote, Partly Remote
BasedLondon, England, United Kingdom; Oxford, England, United Kingdom
HiringNo
Sitehttps://www.ochre-bio.com/

The full profile

Checking your access…

Is this you?

If you're behind Ochre Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.

Sourced from the company's Y Combinator directory entry.

Tools for this story

Each opens in a new tab, filled in for Ochre Bio. With no account yet, you sign up free and land on the result.

Cite this page

Permanent URL: https://mentionfox.com/funding/yc-ochre-bio
Last updated 2026-09-26
Primary record: Y Combinator directory entry
Ochre Bio (YC W20) — RNA medicines for liver diseases. MentionFox, 2026-09-26. https://mentionfox.com/funding/yc-ochre-bio